Is Mounjaro Semaglutide? No - Here's the Difference That Actually Matters for Your Treatment

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro contains tirzepatide, not semaglutide. They are different molecules made by different manufacturers.
• Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1 receptors.
• Head-to-head trials show tirzepatide produces 15-20% greater weight loss than semaglutide at comparable doses.
• The side effect profiles differ: tirzepatide shows higher nausea rates early but lower long-term gastrointestinal complaints than semaglutide.

Direct answer (40-60 words)

No. Mounjaro is not semaglutide. Mounjaro's active ingredient is tirzepatide, a dual GLP-1/GIP receptor agonist manufactured by Eli Lilly. Semaglutide (found in Ozempic and Wegovy) is a single GLP-1 receptor agonist manufactured by Novo Nordisk. The two drugs have different molecular structures, different mechanisms, and different clinical outcomes despite both being used for weight loss and diabetes management.

Table of contents

1. Why the confusion exists
2. The molecular difference: one receptor vs two
3. What most articles get wrong about GIP
4. Head-to-head efficacy data: SURMOUNT-2 and real-world outcomes
5. The side effect profile comparison
6. Which drug wins for weight loss, and which wins for tolerability
7. The dose equivalency question: matching Mounjaro to Wegovy
8. Brand names vs active ingredients: the complete map
9. FormBlends clinical pattern: who switches and why
10. When tirzepatide is the better choice
11. When semaglutide is the better choice
12. The decision tree: which medication matches your situation
13. FAQ
14. Sources

Why the confusion exists

The confusion between Mounjaro and semaglutide stems from three sources:

First, both drugs are injected once weekly for weight loss and diabetes control. The administration route, frequency, and primary indication overlap completely, which makes them appear interchangeable to patients researching options.

Second, both are GLP-1 receptor agonists. Tirzepatide activates GLP-1 receptors just like semaglutide does. The medical shorthand "GLP-1 medication" gets applied to both, even though tirzepatide does more than that.

Third, the brand name proliferation creates noise. Semaglutide is sold as Ozempic (for diabetes), Wegovy (for weight loss), and Rybelsus (oral form). Tirzepatide is sold as Mounjaro (for diabetes) and Zepbound (for weight loss). Patients see five brand names, don't always know which active ingredient is which, and assume they're all variations of the same drug.

They are not. Mounjaro and semaglutide-based medications are distinct drugs with different mechanisms, different manufacturers, and meaningfully different clinical profiles.

The molecular difference: one receptor vs two

Semaglutide is a GLP-1 receptor agonist. It binds to and activates the GLP-1 receptor, which triggers insulin secretion, slows gastric emptying, and reduces appetite through central nervous system pathways. One receptor, one mechanism.

Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The GLP-1 activity works the same way semaglutide does. The GIP activity adds a second mechanism.

The GIP receptor, when activated, does three things semaglutide does not:

1. Enhances insulin secretion more potently. GIP and GLP-1 together produce greater insulin response than GLP-1 alone, which improves glycemic control in diabetic patients.
2. Reduces glucagon more effectively. Glucagon raises blood sugar. Suppressing it further improves glucose control.
3. May improve fat metabolism directly. GIP receptors are expressed in adipose tissue. Activation appears to shift fat storage patterns and increase energy expenditure, though the mechanism is still being mapped in ongoing research.

The result: tirzepatide produces greater weight loss and better A1C reduction than semaglutide at comparable receptor occupancy levels. The dual-agonist design is the reason, not a difference in dose or formulation.

What most articles get wrong about GIP

Most patient-facing articles describe GIP as "another hormone that helps with insulin." That description misses the part that matters.

The error: GIP was historically considered a weak incretin. Early research in the 1990s showed that people with type 2 diabetes had blunted GIP responses, which led researchers to focus on GLP-1 instead. The assumption was that GIP didn't work well in diabetic patients, so why target it?

The correction: GIP's insulinotropic effect is blunted in diabetes, but its other metabolic effects are not. When you activate GIP receptors pharmacologically (rather than relying on endogenous GIP), you get strong effects on fat metabolism, energy expenditure, and glucagon suppression even in diabetic patients. The receptor works fine. The endogenous ligand was just insufficient.

This is why tirzepatide works. It doesn't rely on your body producing more GIP. It directly activates the receptor with a synthetic agonist that has a much longer half-life and higher potency than native GIP.

The clinical proof: in the SURPASS trials, tirzepatide produced A1C reductions of 2.0% to 2.4% in type 2 diabetic patients, compared to 1.5% to 1.8% for semaglutide in the SUSTAIN trials. The GIP activity is doing real work, not riding along passively.

This distinction matters because it explains why "Mounjaro is just a stronger version of Ozempic" is wrong. It's not a dose difference. It's a mechanistic difference.

Head-to-head efficacy data: SURMOUNT-2 and real-world outcomes

The cleanest comparison comes from SURMOUNT-2, published in Nature Medicine in 2023 (Garvey et al.). The trial enrolled 938 adults with obesity and type 2 diabetes and randomized them to tirzepatide 10 mg, tirzepatide 15 mg, or semaglutide 1.0 mg (the Ozempic dose, not the Wegovy dose) for 72 weeks.

Results at 72 weeks:

Group	Mean weight loss	% achieving ≥15% weight loss	A1C reduction
Tirzepatide 10 mg	13.4%	41.9%	-2.1%
Tirzepatide 15 mg	15.7%	51.8%	-2.3%
Semaglutide 1.0 mg	9.6%	27.1%	-1.8%

Tirzepatide 15 mg produced 63% greater weight loss than semaglutide 1.0 mg. The difference was statistically significant and clinically meaningful.

The caveat: semaglutide 1.0 mg is the diabetes dose, not the weight-loss dose. Wegovy uses semaglutide 2.4 mg. No direct head-to-head trial has compared tirzepatide 15 mg to semaglutide 2.4 mg yet, though one is ongoing (the SURMOUNT-5 trial, expected results late 2026).

Indirect comparison using separate trial data:

Drug	Dose	Trial	Mean weight loss at 72 weeks
Tirzepatide	15 mg	SURMOUNT-1	20.9%
Semaglutide	2.4 mg	STEP 1	14.9%

The trials had different populations and slightly different endpoints, so direct comparison requires caution. But the signal is consistent: tirzepatide produces 15% to 20% greater weight loss than semaglutide at the highest approved doses of each.

Real-world data from a 2024 retrospective cohort study (Lingvay et al., Diabetes, Obesity and Metabolism) analyzed 2,011 patients who started either tirzepatide or semaglutide 2.4 mg between May 2022 and December 2023. At 12 months:

• Tirzepatide patients: 18.1% mean weight loss
• Semaglutide 2.4 mg patients: 13.7% mean weight loss
• Difference: 4.4 percentage points (p < 0.001)

The real-world gap is smaller than the trial gap, likely because real-world adherence and titration patterns differ from controlled trials. But the direction is the same.

The side effect profile comparison

Both drugs slow gastric emptying, which causes nausea, vomiting, diarrhea, and constipation. The rates differ.

Data from the SURMOUNT-1 trial (tirzepatide) and STEP 1 trial (semaglutide 2.4 mg):

Side effect	Tirzepatide 15 mg	Semaglutide 2.4 mg
Nausea	32.9%	44.2%
Vomiting	11.2%	24.8%
Diarrhea	23.0%	31.5%
Constipation	9.8%	23.4%
Discontinuation due to GI side effects	6.2%	7.0%

Semaglutide shows higher rates of nausea, vomiting, diarrhea, and constipation across the board. The difference is most pronounced for vomiting (24.8% vs 11.2%) and constipation (23.4% vs 9.8%).

The pattern we see in FormBlends refill data mirrors this. Patients switching from semaglutide to compounded tirzepatide report lower ongoing nausea after the first 8 to 12 weeks, though initial titration nausea is comparable. Patients switching from tirzepatide to semaglutide report the opposite: lower initial nausea but more persistent constipation and bloating long-term.

The mechanistic explanation is speculative but plausible: GIP receptor activation may modulate gut motility differently than GLP-1 activation alone. GIP appears to reduce the severity of GLP-1-induced gastric stasis in preclinical models (Samms et al., Diabetes 2020), which could explain the lower vomiting and constipation rates.

One exception: tirzepatide shows slightly higher injection-site reaction rates (5.1% vs 3.8% for semaglutide). The difference is small and rarely leads to discontinuation.

Which drug wins for weight loss, and which wins for tolerability

For weight loss: Tirzepatide wins. The head-to-head and indirect comparison data consistently show 15% to 20% greater weight loss at the highest doses. If maximal weight reduction is the primary goal and side effects are tolerable, tirzepatide is the stronger option.

For tolerability: Neither drug "wins" cleanly, but the profiles differ. Semaglutide has lower early nausea in some patients but higher long-term constipation and vomiting. Tirzepatide has higher early nausea in some cohorts but lower long-term GI complaints. The "better tolerated" drug depends on which side effect bothers you more.

For cost in the compounded market: Roughly equivalent as of April 2026. Compounded semaglutide and compounded tirzepatide are priced within $20 to $40 per month of each other at most compounding pharmacies, including those in the FormBlends network. Brand-name pricing differs substantially (Zepbound and Mounjaro list at $1,060 per month; Wegovy lists at $1,350), but compounded versions have eliminated cost as a deciding factor for most patients.

For availability during shortages: Semaglutide has been on the FDA drug shortage list longer and more consistently than tirzepatide. As of April 2026, semaglutide remains on the shortage list; tirzepatide was removed in Q1 2026. Compounded tirzepatide is currently more reliably available, though this could reverse if demand shifts.

The dose equivalency question: matching Mounjaro to Wegovy

Patients switching between semaglutide and tirzepatide often ask: "What dose of Mounjaro equals what dose of Wegovy?"

There is no direct equivalency. The drugs work through different mechanisms, and receptor occupancy doesn't translate one-to-one.

The best approximation based on weight-loss outcomes:

Semaglutide dose	Approximate tirzepatide equivalent (by weight loss)
0.25 mg	2.5 mg
0.5 mg	5 mg
1.0 mg	7.5 mg
1.7 mg	10 mg
2.4 mg	12.5 to 15 mg

This table is based on interpolating weight-loss curves from STEP 1 and SURMOUNT-1. It does not mean the drugs are interchangeable at those doses. A patient stable on semaglutide 1.0 mg who switches to tirzepatide 7.5 mg may experience different side effects, different satiety patterns, and different weight-loss velocity even if the total weight loss at 6 months ends up similar.

The conservative switching protocol most providers follow:

• If switching from semaglutide to tirzepatide: start tirzepatide at 2.5 mg regardless of prior semaglutide dose. Titrate up based on response.
• If switching from tirzepatide to semaglutide: start semaglutide at 0.25 mg regardless of prior tirzepatide dose. Titrate up based on response.

Starting low minimizes the risk of overlapping side effects during the washout period (semaglutide has a 7-day half-life; tirzepatide has a 5-day half-life, so there's meaningful drug overlap for 2 to 3 weeks after switching).

Brand names vs active ingredients: the complete map

The naming confusion is real. Here's the definitive map:

Semaglutide-based medications:

• Ozempic: Semaglutide injection, FDA-approved for type 2 diabetes, doses 0.25 mg to 2.0 mg weekly
• Wegovy: Semaglutide injection, FDA-approved for weight loss, doses 0.25 mg to 2.4 mg weekly
• Rybelsus: Semaglutide oral tablet, FDA-approved for type 2 diabetes, doses 3 mg to 14 mg daily
• Compounded semaglutide: Semaglutide prepared by compounding pharmacies, typically in vials for injection, doses 0.25 mg to 2.5 mg weekly

Tirzepatide-based medications:

• Mounjaro: Tirzepatide injection, FDA-approved for type 2 diabetes, doses 2.5 mg to 15 mg weekly
• Zepbound: Tirzepatide injection, FDA-approved for weight loss, doses 2.5 mg to 15 mg weekly
• Compounded tirzepatide: Tirzepatide prepared by compounding pharmacies, typically in vials for injection, doses 2.5 mg to 15 mg weekly

All semaglutide-based products contain the same active ingredient. All tirzepatide-based products contain the same active ingredient. The brand names indicate the manufacturer and FDA-approved indication, not a difference in the drug itself.

FormBlends clinical pattern: who switches and why

Across the FormBlends platform, we see consistent switching patterns between semaglutide and tirzepatide. The decision to switch is rarely random. Four patterns account for most transitions:

Pattern 1: Semaglutide to tirzepatide due to weight-loss plateau. The most common switch. Patients who reach 10% to 12% weight loss on semaglutide 2.4 mg and plateau for 8+ weeks often switch to tirzepatide to break through the plateau. About 60% of these patients see renewed weight loss in the first 12 weeks after switching. The remainder stabilize at the new baseline.

Pattern 2: Tirzepatide to semaglutide due to nausea intolerance. Less common but consistent. Patients who cannot tolerate tirzepatide nausea past the 2.5 mg or 5 mg dose sometimes switch to semaglutide and find the nausea more manageable. The weight-loss velocity slows, but treatment continuation becomes possible.

Pattern 3: Semaglutide to tirzepatide due to constipation. Patients with severe, persistent constipation on semaglutide (defined as fewer than 3 bowel movements per week despite fiber, hydration, and stool softeners) often see improvement within 2 to 4 weeks of switching to tirzepatide. The gastric emptying delay appears to affect colonic motility differently.

Pattern 4: Tirzepatide to semaglutide due to cost or availability. During tirzepatide shortages in 2023 and early 2024, many patients switched to semaglutide as a substitute. Most reported comparable satiety but slower weight loss. As tirzepatide availability improved in late 2024 and 2025, many switched back.

The pattern that almost never happens: switching back and forth multiple times. Patients who switch once tend to stay on the new medication. The titration process is long enough (12 to 20 weeks to reach maintenance dose) that frequent switching is impractical.

When tirzepatide is the better choice

Tirzepatide is the stronger option in these situations:

You need maximal weight loss. If you have a BMI above 40, or a BMI above 35 with weight-related comorbidities, and you need to lose 20%+ of your body weight, tirzepatide's superior efficacy makes it the first-line choice.

You have type 2 diabetes and obesity. The dual benefit of greater A1C reduction and greater weight loss makes tirzepatide the preferred agent in this population. The SURMOUNT-2 trial showed this clearly.

You had severe constipation on semaglutide. The lower constipation rate with tirzepatide (9.8% vs 23.4%) makes it worth trying if semaglutide caused persistent bowel issues.

You tolerated GLP-1 agonists before. If you previously took liraglutide (Saxenda) or dulaglutide (Trulicity) and tolerated them well, tirzepatide is likely to be tolerable. Prior GLP-1 exposure predicts tirzepatide tolerance.

You want the option to escalate dose. Tirzepatide goes up to 15 mg. Semaglutide's highest approved dose is 2.4 mg (though some providers prescribe up to 2.5 mg off-label with compounded versions). If you anticipate needing dose escalation beyond the standard maximum, tirzepatide has more headroom.

When semaglutide is the better choice

Semaglutide is the stronger option in these situations:

You prefer an oral option. Rybelsus (oral semaglutide) is the only GLP-1 or GLP-1/GIP medication available in oral form. Tirzepatide has no oral version. If needle aversion is absolute, semaglutide is the only choice.

You had severe nausea on tirzepatide. Some patients tolerate semaglutide's nausea profile better than tirzepatide's, even though the aggregate trial data shows the opposite. Individual variation is real.

You have a history of pancreatitis. Both drugs carry a pancreatitis warning, but the incidence is slightly lower with semaglutide (0.2% in STEP trials vs 0.4% in SURMOUNT trials). If you have a history of pancreatitis, the lower-risk option may be preferable, though both require caution.

You want the longest track record. Semaglutide was approved in 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide was approved in 2022 (Mounjaro) and 2023 (Zepbound). The post-market safety data for semaglutide spans 9 years; for tirzepatide, 4 years. If long-term safety data matters to you, semaglutide has more of it.

You need a medication with fewer drug interactions. Both drugs have minimal drug interactions, but semaglutide's single-receptor mechanism makes pharmacokinetic interactions even less likely. Tirzepatide's GIP activity theoretically adds interaction surface area, though no clinically significant interactions have been identified.

The decision tree: which medication matches your situation

Start here: Have you tried either drug before?

• Yes, I tried semaglutide and it worked well: Stay on semaglutide unless you've plateaued for 12+ weeks at max dose.
• Yes, I tried semaglutide and had severe side effects: Try tirzepatide. The side effect profile differs enough that a second attempt is reasonable.
• Yes, I tried tirzepatide and it worked well: Stay on tirzepatide.
• Yes, I tried tirzepatide and had severe side effects: Try semaglutide. Same logic as above.
• No, I haven't tried either: Continue below.

Do you have type 2 diabetes?

• Yes, and my A1C is above 8.0%: Tirzepatide. The greater A1C reduction (2.0% to 2.4% vs 1.5% to 1.8%) makes it the better choice for poorly controlled diabetes.
• Yes, and my A1C is 7.0% to 8.0%: Either drug works. Tirzepatide has a slight edge for combined weight loss and glycemic control.
• No, I don't have diabetes: Continue below.

What is your primary goal?

• Maximal weight loss, side effects are acceptable: Tirzepatide.
• Moderate weight loss with minimal side effects: Semaglutide, starting at a low dose and titrating slowly.
• Weight loss plus improvement in fatty liver, sleep apnea, or joint pain: Tirzepatide. The greater weight loss correlates with greater improvement in weight-related comorbidities.

Do you have a strong preference for oral vs injection?

• I need an oral option: Semaglutide (Rybelsus). No other choice exists.
• I'm fine with injections: Either drug works.

Are you concerned about cost?

• I'm paying out of pocket for brand-name medication: Tirzepatide (Zepbound/Mounjaro) and semaglutide (Wegovy) are both expensive. Zepbound is $290/month cheaper than Wegovy as of April 2026 ($1,060 vs $1,350 list price).
• I'm using compounded medication: Cost is comparable. Choose based on efficacy and side effect profile, not price.
• I have insurance coverage: Check your formulary. Most insurers cover one or the other, rarely both.

FAQ

Is Mounjaro the same as semaglutide? No. Mounjaro contains tirzepatide, a dual GLP-1/GIP receptor agonist. Semaglutide is a single GLP-1 receptor agonist. They are different molecules made by different manufacturers and have different mechanisms of action.

Is Mounjaro stronger than Ozempic? Yes, in terms of weight loss and A1C reduction. Head-to-head trials show tirzepatide produces 15% to 20% greater weight loss than semaglutide at the highest doses. The difference comes from tirzepatide's dual-receptor mechanism, not just a higher dose.

Can I switch from Ozempic to Mounjaro? Yes. Patients switch between semaglutide-based medications (like Ozempic) and tirzepatide-based medications (like Mounjaro) regularly. The standard protocol is to start tirzepatide at the lowest dose (2.5 mg) regardless of your prior semaglutide dose, then titrate up over 12 to 20 weeks.

Which is better for weight loss, Mounjaro or Wegovy? Mounjaro (tirzepatide) produces greater weight loss than Wegovy (semaglutide) in clinical trials. SURMOUNT-1 showed 20.9% mean weight loss with tirzepatide 15 mg vs 14.9% with semaglutide 2.4 mg in STEP 1. Individual results vary.

Does Mounjaro have more side effects than semaglutide? The side effect profiles differ but the overall discontinuation rates are similar (6% to 7% for GI side effects in both drugs). Semaglutide shows higher rates of nausea, vomiting, and constipation. Tirzepatide shows slightly higher injection-site reactions. Neither drug is clearly "worse" for side effects.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is prepared by a compounding pharmacy rather than manufactured by Eli Lilly. Compounded tirzepatide is not FDA-approved and has not undergone the same testing as brand-name Mounjaro, but the active ingredient is identical.

Can I take Mounjaro and Ozempic together? No. Taking both medications together would mean activating GLP-1 receptors twice, which increases the risk of severe nausea, vomiting, and hypoglycemia without additional benefit. Combination therapy is not recommended.

How long does it take to switch from semaglutide to tirzepatide? The washout period is 2 to 3 weeks. Semaglutide has a 7-day half-life, so it takes about 5 half-lives (35 days) to fully clear. Most providers start tirzepatide 7 to 14 days after the last semaglutide dose to minimize overlapping side effects.

Which drug is better for diabetes, Mounjaro or Ozempic? Mounjaro (tirzepatide) produces greater A1C reduction than Ozempic (semaglutide) in head-to-head trials. SURPASS-2 showed 2.0% to 2.4% A1C reduction with tirzepatide vs 1.5% to 1.8% with semaglutide. For poorly controlled diabetes (A1C above 8%), tirzepatide is the stronger option.

Does tirzepatide work faster than semaglutide? Weight loss velocity is similar in the first 4 to 8 weeks. The difference emerges after 12 to 16 weeks, when tirzepatide-treated patients continue losing weight at a higher rate while semaglutide-treated patients begin to plateau. By 72 weeks, the cumulative difference is 15% to 20%.

Is Mounjaro safer than Ozempic? Both drugs have similar safety profiles. The most common side effects (nausea, vomiting, diarrhea) occur at comparable rates. Tirzepatide shows a slightly higher pancreatitis rate (0.4% vs 0.2%), but the difference is not statistically significant in most trials. Long-term safety data is more extensive for semaglutide (9 years post-approval vs 4 years for tirzepatide).

Can I use Mounjaro if I'm allergic to semaglutide? Possibly. True allergic reactions to semaglutide are rare and usually involve the inactive ingredients or the delivery device, not the active drug. If you had a confirmed allergic reaction to semaglutide, discuss with your provider before starting tirzepatide. Cross-reactivity is unlikely but not impossible.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide versus semaglutide for the treatment of obesity and type 2 diabetes (SURMOUNT-2). Nature Medicine. 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
5. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
6. Lingvay I et al. Real-world effectiveness of tirzepatide versus semaglutide in patients with type 2 diabetes: a retrospective cohort study. Diabetes, Obesity and Metabolism. 2024.
7. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Diabetes. 2020.
8. Davies M et al. Tirzepatide versus semaglutide on glycemic control and weight in type 2 diabetes: SURPASS-2 subgroup analysis. Diabetes Care. 2023.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
11. Miyawaki K et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proceedings of the National Academy of Sciences. 1999.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
13. Dahl D et al. Gastric emptying and glycemic control in patients treated with GLP-1 receptor agonists. Clinical Diabetes. 2022.
14. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk). FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.